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Predicting mutations that enhance protein–protein
afﬁnity remains a challenging task, especially for
high-afﬁnity complexes. To test our capability to improve
the afﬁnity of such complexes, we studied interaction of
acetylcholinesterase with the snake toxin, fasciculin.
Using the program ORBIT, we redesigned fasciculin’s
sequence to enhance its interactions with Torpedo
californica acetylcholinesterase. Mutations were predicted
in 5 out of 13 interfacial residues on fasciculin, preserving
most of the polar inter-molecular contacts seen in the
wild-type toxin/enzyme complex. To experimentally
characterize fasciculin mutants, we developed an efﬁcient
strategy to over-express the toxin in Escherichia coli, fol-
lowed by refolding to the native conformation. Despite
our predictions, a designed quintuple fasciculin mutant
displayed reduced afﬁnity for the enzyme. However,
removal of a single mutation in the designed sequence
produced a quadruple mutant with improved afﬁnity.
Moreover, one designed mutation produced 7-fold
enhancement in afﬁnity for acetylcholinesterase. This led
us to reassess our criteria for enhancing afﬁnity of the
toxin for the enzyme. We observed that the change in the
predicted inter-molecular energy, rather than in the total
energy, correlates well with the change in the experimental
free energy of binding, and hence may serve as a criterion





Computational protein design has been used frequently to
predict stabilizing mutations (Malakauskas and Mayo, 1998),
to repack protein cores and to redesign entire protein
sequences (Dahiyat and Mayo, 1997). Design of protein–
protein binding interactions is one of the directions in the
ﬁeld that presents particular interest. Indeed, the capability of
creating a binding partner for any given protein would allow
us to construct inhibitors for a speciﬁc disease-associated
pathway, thus revolutionizing the pharmaceutical industry.
However, to date, only relatively few studies have
reported successful redesign of protein–protein interfaces.
Computational methods have been used to substantially
increase protein binding speciﬁcity in calmodulin-target
complexes (Shifman and Mayo, 2002, 2003; Yosef et al.,
2009) and to supply proteins with novel binding speciﬁcities
(Reina et al., 2002; Kortemme et al., 2004; Joachimiak et al.,
2006). Introduction of computationally designed mutations at
protein–protein interfaces helped to convert a native homodi-
mer to a heterodimer (Bolon et al., 2005), and to construct
chimeric proteins with novel DNA-binding properties
(Chevalier et al., 2002). Optimization of electrostatic poten-
tial between two proteins was shown to increase association
rates signiﬁcantly (Selzer et al., 2000; Kiel et al., 2004).
It remains difﬁcult, however, to use existing protein
design methodology to predict afﬁnity-enhancing mutations
of residues located at protein–protein binding interfaces.
Computational design of point mutations intended to
increase binding afﬁnity have met with variable success,
while redesign of entire binding interfaces was often found
to result in reduced afﬁnities (Shifman and Mayo, 2003;
Clark et al., 2006; Palmer et al., 2006; Song et al., 2006).
A recent study by Kuhlman and colleagues suggests an
approach that predicts single afﬁnity-enhancing mutations
by substituting polar residues at the binding interface by
hydrophobic residues, and hydrophobic residues by larger
hydrophobic residues (Sammond et al., 2007). This
approach, probably the most successful so far, cannot,
however, be applied to the redesign of entire binding inter-
faces, since it is inherently bound to increase the hydropho-
bicity of the individual proteins, thus enhancing their
propensity to aggregate. In addition, removal of polar resi-
dues at the binding interface is likely to reduce the binding
speciﬁcity of the bio-molecular interaction, which is
usually not desirable. We set as our goal the development
of a more general strategy for predicting afﬁnity-enhancing
mutations in protein complexes. Such a strategy would
allow for the improvement of both polar and hydrophobic
interactions at protein–protein interfaces.
As our model system we chose a complex of the synaptic
enzyme, acetylcholinesterase (AChE) with a polypeptide
toxin present in the venom of the green mamba, fasciculin-2
(Fas). There were several reasons for this choice. First, the
interaction displays a very high afﬁnity (Karlsson et al.,
1985; Eastman et al., 1995; Radic et al., 1995), thus making
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Secondly, structural studies reveal that no substantial confor-
mational change occurs upon binding (Bourne et al., 1995;
Harel et al., 1995; Kryger et al., 2000), thus simplifying the
design and the analysis procedures. Lastly, a convenient
assay is available for assessing the changes in the afﬁnity of
Fas for AChE.
AChE is a synaptic enzyme that terminates impulse
transmission at cholinergic synapses by rapid hydrolysis of
the neurotransmitter, acetylcholine (Zimmerman and Soreq,
2006). Fas is a snake venom polypeptide toxin that is a very
powerful reversible inhibitor of AChE (Karlsson et al.,
1985); it belongs to the family of three-ﬁnger toxins that
share a common structural motif: a b-sheet core stabilized by
four disulﬁde bridges and three protruding loops that
resemble human ﬁngers (Kini, 2002). The crystal structure of
the Fas/AChE complex has been solved for Torpedo
californica AChE (TcAChE), mouse AChE (mAChE) and
human AChE (hAChE) (Bourne et al., 1995; Harel et al.,
1995; Kryger et al., 2000). The three structures are almost
super-imposable, with Fas binding at the peripheral anionic
site of the enzyme, thus sealing the narrow gorge that
leads to the active site (Fig. 1B). Complexes of Fas with
mammalian AChEs display very high afﬁnities (Kd values of
10
211–10
212 M) (Karlsson et al., 1985; Eastman et al.,
1995; Radic et al., 1995). A weaker, yet still high afﬁnity
(Kd of 4   10
210 M) was reported for the complex between
Fas and TcAChE (Weiner et al., 2009). The tight binding
between these two proteins has been attributed to several
factors, including a remarkable surface complementarity, a
large hydrophobic surface burial accompanying binding and
formation of several inter-molecular hydrogen bonds (Harel
et al., 1995). In addition, electrostatic interactions between
cationic residues on the interaction surface of Fas and
anionic residues on the interaction surface of AChE play an
important role in the binding process (Radic et al., 1997).
A few studies have been performed to determine the con-
tribution of individual amino acid residues of Fas to the
interaction between the two proteins. Karlsson and coworkers
neutralized positive charges on Fas by chemical modiﬁcation
of single lysines or arginines, and reported a substantial
decrease in Fas activity (Cervenansky et al., 1994;
Cervenansky et al., 1995). Marchot et al. used structural and
kinetic data to construct 14 single and double Fas mutants
(Marchot et al., 1997). They assayed these mutants on mouse
AChE (mAChE), measuring inhibitory activity by an indirect
assay based on titration of the mutants with a polyclonal
anti-Fas serum. Seven of these mutants lost some or all their
afﬁnity for the enzyme compared to that of wild-type Fas
(Fas
WT), while four mutants showed no change in afﬁnity.
The remaining three Fas mutants surprisingly exhibited an
increased inhibitory activity against mAChE. However, the
authors suggested that this may reﬂect immuno-dominant
determinants in these regions or intra-molecular rearrange-
ments in conformation that enhance the interaction (Marchot
et al., 1997). In contrast to the earlier studies, we chose to
develop a quantitative computational approach in attempt to
optimize the Fas–AChE interaction. Mutations in Fas that
were computationally predicted to stabilize the Fas/TcAChE
complex were tested experimentally by expressing the Fas
mutants and measuring their binding afﬁnity for TcAChE. To
this end, we developed a reproducible and efﬁcient method-
ology for overexpression and refolding of WT and mutant
forms of Fas in Escherichia coli. This was a challenging task
due both to the small size of Fas (61 residues) and to the fact
that it contains four intra-chain disulﬁdes (Fig. 1A).
Materials and methods
Computational design
The protein redesign program ORBIT was used for Fas
design (Dahiyat and Mayo, 1997). The residues on Fas that
are within 4 A ˚ of TcAChE in the Fas–TcAChE complex
structure (Harel et al., 1995) were selected for optimization
(positions 6, 8, 9, 11, 12, 27, 29, 32, 33, 34, 35, 37 and 61).
All amino acids, except for Pro, Cys and Gly, were con-
sidered at all the design positions. The residues on TcAChE
that are within 4 A ˚ of Fas in the Fas–TcAChE complex
structure were allowed to change their side-chain confor-
mation. Rotamer libraries used for the Fas–TcAChE optimiz-
ations were based on the backbone-dependent library of
Dunbrack and Karplus (Dunbrack and Karplus, 1993), with
additional rotamers expanded by one standard deviation
around their mean x1 and x2 values for all residues except
Lys and Arg. A potential energy function that included terms
for Van der Waals, electrostatic and hydrogen bonding inter-
actions, and for surface area-based solvation, was used to
calculate side chain/side chain and side chain/backbone pair-
wise interactions as described (Dahiyat and Mayo, 1997;
Gordon et al., 1999; Street and Mayo, 1999). In the Fas
design, we used the ORBIT energy function that was opti-
mized to better reproduce the side-chain conformations in
the data set of protein–protein interfaces (O. Sharabi and
J. M. Shifman, in preparation). In this energy function, the
value of the distance-dependent dielectric constant used to
calculate the electrostatic interactions was set to 10r (where r
is distance between two atoms) and the penalty for hydro-
phobic burial, sp, was set to 0.005 kcal mol
21 A ˚ 22. The cal-
culated energies served as input to a side-chain selection
Fig. 1. (A) The amino acid sequence of Fas, showing the four intra-chain
disulphide bridges and the interfacial residues chosen for redesign. (B) The
Fas/TcAChE binding interface before redesign; (C) The Fas/TcAChE
binding interface after redesign. Fas (pink) sits at the entrance of the narrow
gorge leading to the active site of TcAChE (gray). The side-chains on Fas
and TcAChE selected for computational optimization are displayed as pink
and blue sticks, respectively. The numbers are shown for the Fas residues for
which afﬁnity-enhancing mutations had been predicted.
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642procedure that used the Dead-End Elimination theorem
(Desmet et al., 1992; Gordon et al., 2003). All optimizations
were performed using a cluster of Xeon computers.
Gene construction
The gene construct encoding Fas
WT was cloned into the
bacterial expression vector pET-25b (Novagen). The pelB
leader peptide was removed from the expression vector in the
cloning process. The genes for the designed Fas mutants
were constructed based on the skeleton of the WT Fas
expression vector using the standard site-directed mutagen-
esis procedure. The full open reading frames of both Fas
WT




WT and Fas mutants were expressed using the E. coli
BL21(DE3) cell line at 378C. Induction was initiated by the
addition of 0.1 mM isopropyl-D-thiogalactopyranoside
(IPTG) when the optical density of the culture had reached
0.8 OD at 600 nm. 3.5 hours after induction, the cells were
harvested by centrifugation, and resuspended in a lysis buffer
containing 50 mM phosphate, 1% Triton X100, lysozyme
(1 mg/L), 15 mM DNase I and 0.1 mM phenylmethylsulfonyl
ﬂuoride, pH 7.8. The cells were sonicated and centrifuged at
16 000 rpm for 20 min at 48C. The pellets containing the
inclusion bodies (IBs) were collected and stored at 2208C.
Refolding of Fas variants
The IBs were dissolved in the denaturing buffer (6 M
GdHCl, 10 mM EDTA, 50 mM phosphate, pH 8.0) by soni-
cating the samples at 08C. Reduction of the disulphide bonds
of the protein samples was carried out by the addition of
0.1 M 1,4-dithiothreitol (DTT), followed by shaking at room
temperature for 2 h. The non-soluble material was removed
by ultracentrifugation of the sample at 35 000 rpm at 48C.
The denatured and reduced Fas samples were puriﬁed by
reversed-phase HPLC using an acetonitrile/water gradient.
The Fas samples eluted at  30% acetonitrile. The concen-
tration of the puriﬁed protein was determined by measuring
the absorption at 280 nm. The puriﬁed Fas samples were
diluted in the denaturing buffer to a ﬁnal concentration of
 10 mM, and slowly dialyzed into the refolding buffer
(0.5 M GdHCl, 0.3 M NaCl, 2 mM reduced glutathione,
1 mM oxidized glutathione, 5 mM EDTA, 100 mM Tris, pH
9.0). To remove the reducing agents, three more rounds of
dialysis were performed against a buffer containing 0.3 M
NaCl, 5 mM EDTA, 100 mM Tris, pH 9.0, at 48C. The
correct molecular mass of the refolded protein was conﬁrmed
by mass spectrometry, and the absence of free SH groups by
use of the Ellman assay (Ellman, 1959).
AChE activity assays
Native, snake-derived fasciculin-II was purchased from
Alomone Laboratories (Jerusalem, Israel). TcAChE was puri-
ﬁed from electric organ tissue of T.californica (Sussman
et al., 1988), and AChE activity essays were performed as
previously described (Ellman et al., 1961). TcAChE at
0.04 nM concentration was pre-incubated for 20 min either
alone or together with a Fas variant at the desired concen-
tration in 50 mM phosphate, pH 8.0, containing 0.1 mg/ml
BSA and 0.01% NaN3. The same assay mixture without the
enzyme was used as a control to monitor non-speciﬁc
substrate hydrolysis and subtracted from the sample readings.
A range of concentrations were explored for each Fas
mutant. The reaction was started by the addition of the sub-
strate acetylthiocholine iodide (ATC) at 0.8 mM and
5,50-Dithiobis-2-nitro-benzoic acid (DTNB) at 0.4 mM. The
increase in absorption at 412 nm was monitored over 1 min
at 10 s intervals, and the initial velocity of the reaction was
calculated from the slope of the line thus obtained. The frac-
tion of TcAChE activity for a particular concentration of a
Fas variant was calculated by dividing the initial velocity of
the reaction by the initial velocity of the reaction in the
absence of Fas. The experiment was repeated for a range of
Fas concentrations to obtain a full inhibitory proﬁle (Fig. 2).
Each curve was ﬁtted to determine the Kd of binding. To ﬁt
the data, we assumed that Fas is a non-competitive inhibitor
of TcAChE (Weiner et al., 2009) that forms a 1:1 complex
with the enzyme, whose afﬁnity is not affected by binding of
substrate to the enzyme. In this assumption, the binding
could be described by a reaction:
Fas þ AChE
Kd
Fas   AChE and the Kd of binding is:
Kd ¼
½Fas ½AChE 
½Fas   AChE 
¼
ð½Fas tot  ½ Fas   AChE Þð½AChE tot  ½ Fas   AChE Þ
½Fas   AChE 
ð1Þ
where [Fas], [AChE] and [Fas . AChE] are the concentrations
of the unbound Fas, free TcAChE and the inactive complex,
respectively, when the system had reached equilibrium.
[Fas]tot and [AChE]tot are the total concentration of Fas and
TcAChE, respectively. The fraction of the residual active
enzyme measured in Fig. 2 then becomes:
f ¼ 1  








ð½AChE tot þ½ Fas tot þ KdÞ




Measurement of the kinetic parameters
To measure the association and the dissociation rates for
interaction of a Fas mutant with TcAChE, we performed the
TcAChE activity assays under conditions that allowed us to
monitor the kinetics of approach to equilibrium. For this
purpose, mixtures of TcAChE at 0.02 nM, and of a Fas
variant in at least 10-fold excess over the TcAChE concen-
tration were pre-incubated with 0.6 mM DTNB for a variable
period of time (usually, 10–70 s). TcAChE activity was
measured immediately after the addition of 1 mM ATC. The
percent of TcAChE activity for the sample pre-incubated for
a certain period of time was calculated by dividing the
measured TcAChE activity of the sample by that of
the sample containing TcAChE in the absence of Fas. To ﬁt
the data, we assumed that Fas binding to TcAChE could be
Design of fasciculin mutants optimized for interaction with acetylcholinesterase




Fas   AChE
When the Fas concentration is much greater than that of
TcAChE, the percentage of enzymatic activity can be
described by the following expression that combines the kon













where [Fas] is the total concentration of Fas at t ¼ 0, and t is
the time elapsed from the addition of Fas. The kinetic data
were ﬁtted using Eq. (3) in order to determine kon and koff.
Results
We used the computational design program ORBIT (Dahiyat
and Mayo, 1997) to optimize the Fas sequence for interaction
with TcAChE. Starting from the X-ray structure of the
Fas–TcAChE complex (Harel et al., 1995), we deﬁned the
Fas–TcAChE binding interface by selecting the residues on
each protein that are within 4 A ˚ of the second protein in the
complex (Fig. 1B). The 13 Fas residues belonging to the
binding interface were simultaneously redesigned, using all
amino acids as possible candidates except for Pro, Cys and
Gly. At the same time, the side chains of 28 residues on
TcAChE were allowed to change their conformations
(Fig. 1B). The optimal Fas sequence was selected by mini-
mizing the total energy of the Fas–TcAChE complex. The
calculation was performed using the energy function opti-
mized for design of partially polar protein–protein interfaces
(see Materials and methods). The optimization yielded a Fas
mutant, Fas
des, with ﬁve interfacial mutations with respect to
Fas
WT: T8V, T9N, R11K, H29R and K32R (Fig. 1C).
To access experimental parameters for the binding of
Fas
des to TcAChE, we ﬁrst had to develop a strategy for
expression of Fas mutants. Fas
WT from the green mamba
venom could be obtained from a commercial source, while
recombinant Fas
WT and Fas mutants had been previously
expressed only in mammalian cells (Marchot et al., 1997).
We chose, however, to express Fas variants in E.coli. The
main challenge in making this choice is the presence of four
intra-chain disulﬁde bonds in a protein as small as Fas,
making it prone to mis-folding when expressed in a prokar-
yotic host. Initially, we attempted to express Fas
WT in strains
of E.coli in which disulﬁde bond formation is enhanced.
Both periplasmic expression and expression in cells in which
mutations had been introduced into the thioredoxin reductase
(trxB) and glutathione reductase (gor) genes (e.g.
Rosetta-Gami(DE3)) were unsuccessful. Although we were
able to obtain some soluble Fas
WT, the protein displayed a
large content of free thiol groups, and exhibited very weak
inhibition of AChE, indicating that the Fas
WT produced was
largely misfolded (data not shown). Hence, we decided to
pursue an alternative strategy that involved expressing of the
Fas
WT as IBs, followed by a refolding procedure. The gene
corresponding to Fas
WT was cloned into the pET-25b vector
and expressed in BL21(DE3) cells. A large amount of the
Fas polypeptide indeed expressed as IBs. The IBs were
denatured and reduced, the Fas was puriﬁed by reverse phase
HPLC and was then slowly refolded making use of
a GSH-GSSG redox buffer. The refolded Fas
WT migrated
identically to commercially available Fas
WT on SDS–PAGE
(insert to Fig. 2). The correct molecular mass of the refolded
protein was conﬁrmed by mass spectrometry, and the
absence of free thiol groups by the Ellman assay (Ellman,
1959). Since the formation of all four disulphide bonds is
highly unlikely to occur in a misfolded species, the absence
of free SH groups in the puriﬁed protein provides strong evi-
dence that the Fas
WT had indeed folded correctly. To further
verify the correctness of the Fas fold, we compared the
inhibitory activity of our refolded Fas
WT against TcAChE to
that of the commercially available Fas
WT. Figure 2 shows
that the inhibitory activities of the two Fas samples are equal
within experimental error. The above experiments clearly
demonstrate that our expression/refolding procedure yields
the correctly folded and fully active Fas
WT in reasonable
quantities ( 1 mg of protein from 1.5 l of E.coli culture).
Next, we used the same procedure to obtain Fas
des. Less than
3% of free SH groups were detected in the protein sample
after refolding, indicating that the correct Fas structure had
been attained for the vast majority of the Fas
des molecules.
To measure the binding afﬁnity of Fas
WT and Fas
des for
TcAChE, we performed TcAChE activity assays in the pres-
ence of each Fas variant. A large range of Fas concentrations
were explored to obtain a full TcAChE inhibition proﬁle
(Fig. 3A). Since binding of Fas to TcAChE inactivates the
enzyme almost completely, the fractional enzymatic activity
is inversely proportional to the Fas-bound enzyme species
and can thus be used to calculate the binding afﬁnity (Kd)o f
Fig. 2. Comparison of recombinant wild-type Fas expressed in E.coli to
native Fas puriﬁed from mamba venom. Activity proﬁles of TcAChE when
inhibited by recombinant wild-type Fas (closed triangle) and by native Fas
(closed circle). [Fas] are plotted on a log scale. TcAChE activity is measured
with an accuracy of +0.05. An insert shows an SDS–PAGE gel for equal
amounts of recombinant Fas (lane 1) and native Fas (lane 2). Molecular
weight markers are shown in the leftmost lane.
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methods]. The Kd of Fas
WT for TcAChE was found to be
0.31+0.07 nM, very similar to the value of 0.4 nM reported
previously (Weiner et al., 2009). Fas
des bound to TcAChE
with a Kd of 1.2+0.2 nM, corresponding to a  0.8 kcal/
mol increase in the free energy of binding, DDGbind,
compared to Fas
WT (Fig. 3B).
To determine whether the increase in DDGbind displayed by
Fas
des is due to a single mutation that is highly destabilizing
for the Fas–TcAChE complex or to the sum of several slightly
destabilizing mutations, we constructed all single mutants
derived from the sequence of Fas
des. In addition, we made a
double mutant, T8V/T9N, to explore the possibility that these
two spatially proximal mutations are energetically coupled.
TcAChE activity measurements in the presence of single and
double Fas mutants are shown in Fig. 3A, while changes in
binding afﬁnity (Kd) and free energy of binding to TcAChE
are summarized in Table I and Fig. 3B. Two mutations, K32R
and T9N, proved to be rather deleterious for Fas binding to
TcAChE, resulting in increases of 1.2 and 1.3 kcal/mol,
respectively, in DDGbind. Mutation R11K destabilized the
Fas–TcAChE complex very slightly, while mutation T8V was
moderately stabilizing. Mutation H29R, however, improved
the binding afﬁnity for TcAChE considerably, producing a
1.1 kcal/mol decrease in DDGbind. The double mutant, T8V/
T9N, exhibited a 0.4 kcal/mol increase in DDGbind.
Simultaneous introduction of the T8V and T9N mutations
destabilized the Fas–TcAChE complex by a smaller amount
compared to the sum of DDGbinds observed for the two indi-
vidual mutations (0.75 kcal/mol). Hence, these two mutations
are indeed energetically coupled. The rest of the single
mutations were additive, producing a 0.84 kcal/mol increase
in DDGbind for the sum of all the designed mutations in the
Fas
des sequence (T8V/T9NþR11KþH29RþK32R) com-
pared to 0.82 kcal/mol measured for Fas
des. In an attempt to
obtain a multiple Fas mutant that would bind to TcAChE
better than Fas
WT, we constructed the Fas
desR32K variant. In
this variant, all the designed mutations were incorporated
except for K32R, which had proved to be the most deleterious
mutation. Fas
desR32K showed an enhanced binding afﬁnity
for TcAChE corresponding to a 0.4 kcal/mol decrease in
DDGbind (Fig. 3B and Table I).
Our computational design procedure seeks to increase the
overall stability of the Fas–TcAChE complex, but cannot
make predictions with respect to changes in the rates of
association and dissociation of the two proteins (kon and koff,
respectively). Nevertheless, it is interesting to measure the
effect of the predicted Fas mutations on the kinetics of the
Fas–TcAChE interaction. To determine kon and koff for inter-
action of the Fas mutants with TcAChE, we performed the
TcAChE activity assays under conditions in which the inter-
action of the two proteins approaches equilibrium. In these
experiments, a Fas mutant was pre-incubated with TcAChE
for various time intervals before the enzymatic activity was
measured (Fig. 4A). At shorter incubation times, the system
has not yet reached equilibrium and a number of the enzyme-
bound Fas molecules depend on the association and the dis-
sociation rates of this bio-molecular interaction. At longer
incubation times, equilibrium is achieved and the fraction of
the enzyme-bound Fas molecules is determined solely by the
equilibrium binding afﬁnity, Kd. The data were then analyzed
using Eq. (3) (see Materials and methods) to obtain kon and
koff (Fig. 4B and C and Table I). Most of the Fas mutants
exhibited very slight changes in kon, the exception being the
H29R mutation, for which a  6-fold increase in kon was
observed. This substantial improvement in kon is consistent
with our computational prediction that H29R introduces a
favorable electrostatic interaction of Fas with TcAChE Asp
285. A slight enhancement in kon is also seen for the
Fig. 3. (A) Residual TcAChE activity in the presence of Fas variants (viz.,
T9N, K32R, Fas
des, R11K, T8V/T9N, Fas
WT,F a s
desR32K, T8V and H29R)
is displayed as a function of their concentrations. TcAChE was maintained at
a concentration of 0.04 nM in all experiments. A wide range of Fas
concentrations were explored in order to encompass the entire activity proﬁle
for each mutant. The curves were ﬁtted to a 1:1 binding model to determine
the Kd values for interaction of TcAChE with the Fas mutants [See Eq. (2)].
Each experiment was repeated two to four times, and the average Kd and the
standard deviation were calculated; (B) DDGbind values for interaction of the
Fas mutants with TcAChE were calculated according to DDGbind¼0.59 kcal/
mol ln [Kd(Fas
mutant)/Kd(Fas
WT)]. The error bars were calculated from the
standard deviations in the Kd values determined by repeating the
experiments shown in (A).
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des. koff was unaltered for the H29R and
R11K mutants. The rest of the Fas mutants (T8V/T9N,
K32R and Fas
des) displayed a several-fold increase in koff.
The Kd values calculated from the kinetic constants are in
good agreement with the Kd values obtained in the equili-
brium experiments (Table I).
Discussion
Our optimization produced a Fas mutant, Fas
des, with a
binding interface composition 62% identical to that of
Fas
WT. In this design procedure, we achieved a wild-type
recovery rate higher than that observed on the average in
protein design studies (51 and 27% in protein cores and sur-
faces, respectively) (Kuhlman and Baker, 2000). In addition,
the optimization almost completely preserved the polar/
hydrophobic content of the Fas
WT/TcAChE interface,
although no hydrophobic patterning had been imposed
during the design. These two results indicate that our energy
function was able to reproduce successfully most of the
favorable interactions in a high-afﬁnity protein–protein
complex. Nevertheless, Fas
des, with the ﬁve designed
mutations, exhibited a  4-fold reduction in afﬁnity for
TcAChE compared to Fas
WT when measured experimentally.
This reduction is attributed to an increase in koff.
Examination of single and double Fas mutants derived from
the Fas
des sequence revealed that the reduced binding afﬁnity
is due primarily to one mutation, K32R, and removal of this
mutation indeed resulted in a Fas mutant displaying
increased afﬁnity for TcAChE. At least one designed
mutation, H29R, enhanced the afﬁnity of the Fas–TcAChE
complex signiﬁcantly, due to enhancement of kon. It should
be noted that this mutation involves substitution of a polar
residue by another polar residue, and does not increase the
buried hydrophobic surface area of the Fas–TcAChE inter-
face, in contrast to the strategy previously suggested for
enhancing protein binding afﬁnity (Sammond et al., 2007).
A closer look at the design results revealed that our best Fas
mutant, H29R, is predicted to considerably improve inter-
molecular interactions between Fas and TcAChE. Our worst
Fas mutant, K32R, in contrast, is predicted to improve inter-
actions within Fas, while slightly destabilizing the Fas–
TcAChE complex. To better understand the shortcomings of
our computational procedure, we calculated the relative ener-
getic contributions of inter- and intra-molecular interactions
for each of the designed Fas mutations. In doing so, we
summed all the molecular interactions considered in the
ORBIT energy function, including van der Waals inter-
actions, electrostatic interactions, hydrogen bonding and sol-
vation. In addition, using the structure of the Fas–mAChE
Fig. 4. (A) TcAChE activity in the presence of Fas mutants under
conditions in which interaction between the two proteins approaches
equilibrium. For clarity, the data for only three mutants are shown: K32R
(closed square), Fas
des (closed circle) and H29R (closed diamond). TcAChE
activity decreases with time until a plateau is reached. Slightly different
concentrations were used for each Fas mutant so as to obtain optimal results.
TcAChE at 0.025 nM was incubated with 0.75 nM Fas
des and 1.25 nM
K32R; TcAChE at 0.006 nM was incubated with 0.15 nM H29R. The data
were ﬁtted to Eq. (3). (B) and (C) summarize the rates of association with
TcAChE (B) and dissociation from the enzyme (C) of the various Fas
mutants. Error bars represent the standard deviation obtained by repeating
the experiments shown in (A). The experiment for K32R was performed
only once.
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646complex, we calculated the same energetic contributions for
Fas mutants whose inhibitory activity towards mAChE had
been reported previously (Marchot et al., 1997). For both
Fas–AChE complexes, we observed only a weak correlation
between the experimentally observed DDGbind and the
change in the total calculated energy of the complex (DEtot)
that was used as a design criterion in this study (Fig. 5A).
However, the correlation improved greatly when the inter-
molecular energy term (DEinter) alone was considered
(Fig. 5B). A correlation coefﬁcient of 0.80 was obtained for
the single, double and quadruple Fas mutants reported in this
study. This correlation coefﬁcient was slightly reduced to
0.74 if the data for the previously reported Fas mutants were
also incorporated. A slightly worse correlation between the
experimental DDGbind and the calculated DEinter was
observed for the quintuple mutant Fas
des. One possible
reason for this discrepancy is accumulation of errors in our
predictions due to slight overestimation of DEinter for each
individual mutation (Fig. 5B). Another source of error might
arise from slight changes in the backbone conformation of
the Fas–TcAChE complex that is not modeled in our study.
Such changes are much more likely to occur when multiple,
rather than single, mutations are introduced into the Fas
sequence.
In our recent study in which calmodulin (CaM) was opti-
mized for interaction with a target peptide, a very strong cor-
relation was observed between the experimental DDGbind and
the calculated DEtot, which is in contrast to our present ﬁnd-
ings (Yosef et al., 2009). This discrepancy can be explained
easily if one takes into account that CaM undergoes a large
conformational change upon binding. Hence, improvement in
binding of CaM to its targets can be achieved not only by
introduction of mutations that improve inter-molecular inter-
actions, but also by introduction of mutations that stabilize
CaM in its target-bound conformation [see also (Shimaoka
et al., 2000)]. In the Fas/TcAChE complex, for which no
substantial conformational change is believed to occur,
mutations that stabilize Fas alone are thus not expected to
improve its binding afﬁnity for TcAChE.
In conclusion, using our computational design procedure,
we were able to identify a single Fas mutant with a signiﬁ-
cantly enhanced binding afﬁnity for TcAChE, and a quadru-
ple Fas mutant with a slightly enhanced binding afﬁnity for
TcAChE. Inspection of our data revealed a better correlation
Fig. 5. Correlation between the experimentally observed change in free
energy of binding, DDGbind, and the change in the calculated energies for
the Fas–TcAChE complex. (A) Correlation with the total energy change,
DEtotal.( B) Correlation with the inter-molecular energy change, DEinter.
(Closed circle) Fas mutants tested for binding to TcAChE in this
study.(Closed inverted triangle) Fas mutants previously tested for binding to
mAChE. We excluded Fas mutants with amino acid deletions or with
mutations outside the Fas–mAChE interface, as well as mutants for which
an exact value of Kd had not been reported. The lines represent the linear
ﬁtting of all the data points except for that for Fas
des.
Table I. Binding parameters for interaction of Fas mutants with TcAChE
Mutant Kd equilibrium
a ,n M DDGbind
b , kcal/mol Kd kinetics
c ,n M kon








WT 0.31+0.07 – 0.37+0.07 6.8+1.5 2.5+0.9
Fas
des 1.2+0.2 0.82 1.02+0.02 11.1+0.6 11.3+0.5
T8V 0.125+0.005 20.53 – – –
T9N 2.8+0.2 1.3 – – –
T8V/T9N 0.64+0.09 0.42 0.60+0.05 8.5+0.7 5.05+0.05
R11K 0.53+0.05 0.31 0.63+0.05 4.7+0.4 2.93+0.02
H29R 0.052+0.009 21.1 0.03+0.02 39.0+3.5 1.27+0.9
K32R 2.3+0.2 1.2 2.6 3.5 9.0
Fas
desR32K 0.16+0.02 20.36 – – –
aKd equilibrium was calculated by ﬁtting the data on Fig. 3A to Eq. (2).
bThe DDGbind is the difference in the experimental binding free energy between the Fas mutant and Fas
WT. It was calculated from Kd equilibrium.
cThese values were calculated by ﬁtting the kinetic data presented in Fig. 4A to Eq. (3).
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647of the experimental DDGbind with the calculated inter-
molecular energy DEinter than with DEtotal. Thus, DEinter may
serve as a better predictive measure for redesign of protein–
protein complexes in which no substantial conformational
changes occur upon binding. A more extensive mutational
study of the Fas–AChE binding interface is under way in
order to test this prediction.
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